Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15547605 | 0.88 | EPHX1 (0.50) | EPHX1FAAHEPHX2PRMT1ALDH1A1 | |
| SCHEMBL10083913 | 0.86 | — | — | |
| SCHEMBL13135023 | 0.85 | EPHX1 (0.61) | EPHX1EPHX2PRMT1MEN1KMT2A | |
| SCHEMBL14198101 | 0.85 | EPHX1 (0.68) | EPHX1EPHX2PRMT1MEN1KMT2A | |
| SCHEMBL9763831 | 0.84 | EPHX1 (0.75) | EPHX1FAAHEPHX2 | |
| SCHEMBL10399741 | 0.83 | EPHX1 (0.73) | EPHX1EPHX2PRMT1MEN1KMT2A | |
| SCHEMBL10645500 | 0.83 | EPHX1 (0.79) | EPHX1FAAHEPHX2 | |
| SCHEMBL969649 | 0.81 | EPHX1 (0.74) | EPHX1EPHX2 | |
| SCHEMBL23173031 | 0.80 | EPHX1 (0.52) | EPHX1EPHX2PRMT1MEN1KMT2A | |
| SCHEMBL2446588 | 0.79 | EPHX1 (0.54) | EPHX1EPHX2PRMT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| US-6977258-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-20 | — | — | US | disclosed |
| US-6972290-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-06 | — | — | US | disclosed |
| US-20050192282-A1 | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | US | disclosed |
| EP-1254899-B1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20050043318-A1 | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | SCHERING AKTIEGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| US-6573266-B1 | Compounds used for treating multitiple sclerosis and encephalomyelitis | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6555537-B2 | Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| US-6534509-B1 | Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | EPHX1 838/4885FAAH 247/4885EPHX2 618/4885 |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | EPHX1 838/4885FAAH 247/4885EPHX2 618/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | EPHX1 987/4885FAAH 2108/4885EPHX2 1391/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | EPHX1 838/4885FAAH 247/4885EPHX2 618/4885 |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | EPHX1 838/4885FAAH 247/4885EPHX2 618/4885 |
| US-20050192282-A1 | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | CCL2, CCL11, CCL5 | EPHX1 2046/4885FAAH 3624/4885EPHX2 2571/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | EPHX1 1403/4885FAAH 1593/4885EPHX2 2184/4885 |
| US-20050043318-A1 | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | CCL2, CCR2, CXCL10 | EPHX1 987/4885FAAH 2108/4885EPHX2 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.